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Bmi1 is required for efficient self-renewal of hemato-
poietic stem cells (HSCs) and leukemic stem cells
(LSCs). In this study, we investigated whether
leukemia-associated fusion proteins, which differ in
their ability to activate Hox expression, could initiate
leukemia in the absence of Bmi1. AML1-ETO and
PLZF-RARa, which do not activate Hox, triggered
senescence in Bmi1/ cells. In contrast, MLL-AF9,
which drives expression of Hoxa7 and Hoxa9, readily
transformedBmi1/ cells. MLL-AF9 could not initiate
leukemia in Bmi1/Hoxa9/ mice, which have
further compromised HSC functions. But either gene
could restore the ability of MLL-AF9 to establish
LSCs in the double null background. As reported for
Bmi1, Hoxa9 regulates expression of p16Ink4a/p19ARF
locus and could overcome senescence induced by
AML1-ETO. Together, these results reveal an impor-
tant functional interplay between MLL/Hox and Bmi1
in regulating cellular senescence for LSC develop-
ment, suggesting that a synergistic targeting of both
molecules is required to eradicate a broader spectrum
of LSCs.
INTRODUCTION
Self-renewal is an essential feature for the maintenance of both
normal and malignant stem cells. Emerging evidence indicates
that pathways critical for self-renewal of normal stem cells are
frequently hijacked by malignant stem cells to sustain their
immortal growth (Reya et al., 2001). A prominent target is the
polycomb group (PcG) protein, Bmi1, which has been shown to
be required for normal development of hematopoietic stem cells
(HSCs), neural stem cells, and mammary epithelial stem cells
(Sauvageau and Sauvageau, 2010). Most notably, in spite of the
critical role of Bmi1 in the self-renewal of multiple somatic stemcells, Bmi1/ mice can survive to adulthood (up to 20 weeks),
suggesting the presence of alternate pathways that may partly
compensate for the lack of Bmi1. In acute myeloid leukemia
(AML) where leukemic stem cells (LSCs) have been functionally
defined (Dick, 2008), chimeric transcription factors (CTFs) result-
ing from chromosomal translocations represent the most
common initiating events (Greaves andWiemels, 2003) for onco-
genic conversion of normal cells into preLSCs and subsequently
LSCs (Hong et al., 2008; Yeung et al., 2010). Bmi1 is required for
self-renewal of LSCs inducedbyMeis1 andHoxa9 oncogenes. In
contrast to wild-type (WT) bone marrow cells transduced with
Meis1 and Hoxa9 that could induce AML in mice upon serial
transplantation, Bmi1/ cells transduced with the same onco-
proteins gradually lost their self-renewal ability and failed to
induceAML in secondary transplantedmice (Lessard andSauva-
geau, 2003). Although this seminal study has led to the discovery
of a previously unrecognized function of Bmi1 in the self-renewal
of LSCs, overexpression of Meis1 and Hoxa9 has not been iden-
tified as being the initiating event in humanAML stemcells, which
are mostly initiated by specific CTFs with distinctive transcrip-
tional functions and targets (Greaves et al., 2003; Greaves and
Wiemels, 2003). It is not clear whether Bmi1 is also required for
the function of bona fide leukemia-associated CTFs in AML
stem cells or whether there are alternative pathways that can
sustain oncogenic self-renewal in the absence of Bmi1. The
most prevalent CTFs arise from mutations of the retinoic acid
receptor (RARa), the core-binding factors (either of its two
subunits, AML1orCBFb), and themixed lineage leukemia protein
(MLL). SuchCTFs canbe functionally classified according to their
dominant transcriptional activities into repressive or activating
transcription factors (Cheung and So, 2011; Look, 1997; So and
Cleary, 2004). Dominant-repressive CTFs, including chimeric
RARa and AML1 oncoproteins, associate with transcriptional
corepressors resulting in suppression of downstream target
genes. In contrast, dominant-activating CTFs, such as MLL
fusion, recruit transcriptional coactivator complexes leading to
the constitutive activation of downstream target genes, including
Hox genes (Ayton and Cleary, 2003; So et al., 2004).
Hox proteins represent a group of functionally conserved
transcription factors involved in the self-renewal of normal andCell Stem Cell 8, 649–662, June 3, 2011 ª2011 Elsevier Inc. 649
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preferentially expressed in HSCs and downregulated during
differentiation (Sauvageau et al., 1994). Enforced expression of
Hoxb4 leads to stem cell expansion and can significantly
enhance long-term hematopoietic reconstitution (Antonchuk
et al., 2002). Hoxa9 forms a leukemogenic fusion with Nup98 in
AML and has also been proposed as one of the crucial targets
for MLL leukemia (Liedtke and Cleary, 2009). However, the crit-
ical downstream targets of Hox remain elusive and deletion of
any single or multiple Hox gene(s) does not lead to any detect-
able stem cell defects with the exception of Hoxa9. Hoxa9/
micemaintained a normal number of HSCs but exhibited weaker
reconstitution ability in a competitive transplantation assay (Law-
rence et al., 2005; So et al., 2004). Together, these results identify
Hox family proteins as critical factors in determining the self-
renewal property of HSCs in spite of strong functional redun-
dancy among the family. During embryonic development, Hox
gene expression is maintained by antagonistic action between
trithorax group (TrxG) proteins such as MLL and PcG proteins
(Schuettengruber et al., 2007). Mutation of PcG or TrxG proteins
results in homeotic transformations associated with aberrant
expression of Hox genes. The homeotic defect in MLL-deficient
murine embryos can be partially rescued by deletion of Bmi1
(Hanson et al., 1999). However, this transcriptional network
may not be operational in the hematopoietic system where the
expression of Hox genes, including Hoxb4, in Bmi1/ HSCs is
not altered (Iwama et al., 2004), suggesting that hematopoietic
self-renewal pathways mediated by endogenous Hox may not
be grossly affected by the absence of Bmi1.
In this study, we discovered that MLL-AF9, which drives
high-level expression of multiple Hox genes, could overcome
Bmi1-deficiency to establish LSCs. We further demonstrated
a functional crosstalk between Hoxa9 and Bmi1 in regulating
cellular senescence for the development of normal hematopoi-
etic and leukemic stem cells. Our results strongly suggest that
a synergistic targeting of both Bmi1 and Hoxa9 is required for
abolition of certain LSCs such as MLL LSCs with alternative
senescence suppression pathways.
RESULTS
Differential Bmi1 Requirement for Transformation
by Leukemia-Associated Fusion Proteins
To investigate the roles of Bmi1 in acute leukemogenesis, we
compared the transformation ability of three common
leukemia-associated CTFs: AML1-ETO-9a (AE), PLZF-RARa
(PR), and MLL-AF9 (MAF9) in primary hematopoietic cells
derived from the bone marrow of wild-type or Bmi1/ mice.
To include all the cellular targets for establishment of LSCs, we
used c-Kit-enriched cells containing both HSCs and progenitors
in the study as previously described (Yeung et al., 2010). As ex-
pected, all these fusion proteins could competently transform
and enhance the replating ability of wild-type primary hemato-
poietic cells as determined using a retroviral transduction and
transformation assay (RTTA), which has been widely employed
as an in vitro surrogate assay for self-renewal properties associ-
ated with these CTFs (Cheung et al., 2007; Kwok et al., 2006,
2009, 2010; Lavau et al., 1997; So et al., 2003; Yeung et al.,
2010; Zeisig et al., 2007; Zeisig and So, 2009) (Figure 1). In650 Cell Stem Cell 8, 649–662, June 3, 2011 ª2011 Elsevier Inc.contrast to vector control transduced cells that exhausted their
self-renewal potential in the second round of plating, cells trans-
formed by these CTFs can be serially replated (Figure 1A) to form
compact CFU-GEMM (colony forming unit—granulocyte, eryth-
rocyte, monocyte, megakarocyte)-like colonies (Figure 1B) with
an immunophenotype (Figure 1C) and morphology (Figure 1D)
consistent with immature myeloid precursors. In the absence
of Bmi1, AE and PR gave rise to very few second- and no
third-round colonies even though transduced cells could yield
a similar number of first-round colonies (see Figure S1A available
online), suggesting a functional dependence of Bmi1 for
extended self-renewal (Figures 1A and 1B), which is also consis-
tent with a recent observation in the RARa fusion (Boukarabila
et al., 2009). In contrast, Bmi1/ cells transduced with MAF9
could still efficiently form colonies in the third and subsequent
rounds of replating (Figure 1A; data not shown) with similar
morphology and immunophenotypes (Figures 1B–1D) as the
wild-type transformed cells. The expression level of CTFs, the
immunophenotypes, and morphology of the cells/colonies
were similar between the wild-type and Bmi1/-transduced
cells (Figures S1B–S1D). To further characterize the in vivo prop-
erties of these cells, we serially transplanted them into syngeneic
mice to assess their leukemogenic potential. MAF9-transformed
cells derived from a Bmi1/ background were able to induce
leukemia in mice, in spite of a slightly reduced penetrance as
compared with MAF9-transformed wild-type cells (Figure 1E).
More importantly, when the primary leukemic cells from these
animals were transplanted into secondary recipients to further
assess their long-term self-renewal property, MAF9 Bmi1/
leukemic cells could efficiently induce leukemia with an even
shorter latency (Figure 1E), indicating that Bmi1 is largely
dispensable for establishment and self-renewal of LSCs gener-
ated by MAF9. Consistently, the bone marrows of transplanted
mice were filled with immature myeloid blasts (Figure 1F), which
also infiltrated into different organs including the spleen and liver
(Figure 1G). Together, these results revealed contrasting depen-
dence on Bmi1 between different CTFs.
AE and PR Trigger p16Ink4a- and p19Arf-Dependent
Senescence in the Absence of Bmi1
Functional complementation experiments were then performed
to investigate the potential function of Bmi1 on AE/PR-mediated
transformation. As expected, AE, PR, or Bmi1 alone could not
transform Bmi1/ hematopoietic cells. Coexpression of Bmi1
restored the transformation ability of AE and PR (Figure 2A;
data not shown). Although transduced cells formed a similar
number of first-round colonies (Figure S2A) and expressed
a similar level of fusion transcripts (Figure S2B), only Bmi1 co-
transduced cells could form compact third-round colonies (Fig-
ure 2B). In spite of slightly higher expression levels of Mac-1 and
c-Kit, they possessed similar immunophenotype (Figure 2C) and
cell morphology (Figure 2D) to wild-type cells transformed by AE
or PR.
As compared with wild-type cells, Bmi1/ cells transduced
with AE or PR exhibited severe proliferation defects (Figure 2E;
Figure S2C) and an increase in noncycling cells (Figure 2F) as
determined by a bromodeoxyuridine (BrdU) incorporation assay,
suggesting a cell-cycle defect. Because Bmi1 is a well-known
negative regulator of the cdkn2a locus encoding cell-cycle
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Figure 1. Differential Bmi1-Dependent Transformation by CTFs
(A) Bar charts represent colony numbers in each round of plating in methylcellulose. Error bars represent standard deviation (SD) from at least three independent
experiments. AE = AML-ETO9a; PR = PLZF-RARa; MAF9 = MLL-AF9.
(B) Typical morphology of third-round colonies from primary BM cells transduced with indicated constructs. Scale bar, 0.2 mm.
(C) Immunophenotype analysis of cells transformed by indicated oncogenes. Dot profiles represent staining obtained with antibodies specific for the indicated
cell surface markers. Contour profiles show unstained controls.
(D) Typical cell morphology of primary BM cells transduced with indicated constructs. Scale bar, 10 mm.
(E) MAF9-transformed Bmi1/ cells induced leukemia in syngeneic mice, which were transplantable into secondary recipients (wild-type, n = 20; primary
Bmi1/, n = 10; secondary Bmi1/, n = 9; untransduced control, n = 10). *p < 0.05 when comparing the survival curve to the control; ns indicates p > 0.05.
(F) Immunophenotype analysis of leukemic cells recovered from BM of Bmi1/: MAF9 injected mice. Dot profiles represent staining obtained with antibodies
specific for the indicated cell surface markers. Contour profiles show unstained controls.
(G) Histology of spleen and liver from leukemic mice injected with Bmi1/: MAF9. Scale bar,10 mm. *p < 0.05 (see also Figure S1).
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Bmi1 and Hox Crosstalk in Establishment of LSCsinhibitors, p16Ink4a and p19Arf, which are linked to cellular senes-
cence, we investigated the effect of these CTFs on their expres-
sion in the presence or absence of Bmi1. The absence of Bmi1
resulted in a small but significant change of p16Ink4a/19Arf
expression in c-Kit-enriched hematopoietic cells (Figure 2G; Fig-
ure S2D). Similarly, AE or PR elicited a relatively mild increase in
p16Ink4a and p19Arf expression in wild-type cells. These were in
a stark contrast to the Bmi1/ cells transduced with AE or PR,
which expressed 60- to 300-fold higher levels of p16Ink4a and
p19Arf than Bmi1/ c-Kit cells (Figure 2G). This increase inp16 expression was also observed at the protein level (Fig-
ure 2H). Levels of p16Ink4a and p19Arf (Figure 2G) also showed
a strong correlation with proliferation (Figure 2E) and cell-cycle
defects (Figure 2F), consistent with the induction of cellular
senescence. Conversely, reintroduction of Bmi1 in AE or
PR-transduced Bmi1/ cells suppressed the expression of
p16Ink4a and p19Arf (Figure 2G) as well as partly reversed the
associated proliferation defects (Figure 2E; Figure S2C) and
senescence (Figure 2F). To further confirm the role of Bmi1
in oncogene-induced senescence (OIS), we performedCell Stem Cell 8, 649–662, June 3, 2011 ª2011 Elsevier Inc. 651
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Figure 2. p16/19 Induced Senescence in Bmi1-Dependent Transformation by AE and PR
(A) Bar charts represent colony numbers generated by transduced Bmi/ cells in each round of plating in methylcellulose for the indicated constructs.
(B) Typical morphology of third-round colonies of primary BM cells transduced with the indicated constructs. Scale bar, 0.2 mm.
(C) Immunophenotype analysis of cells transformed by the indicated constructs. Dot profiles represent staining obtained with antibodies specific for the indicated
cell surface markers. Contour profiles show unstained controls.
(D) Typical cell morphology from primary BM cells transduced with indicated constructs. Scale bar, 10 mm.
(E) Bar chart indicates the fold change in cell number after 1 week of growth in OP9 coculture assays for AE (left) and PR (right) transduced cells.
(F)Bar chartsshowproportionofcyclingcells (BrdU+) ornoncyclingcells (BrdU) inAEandPR-transformedBmi1/primaryBMwithorwithout reintroductionofBmi1.
(G) p16INK4a (left) and p19ARF levels (right) after reintroduction of Bmi1 in AE and PR-transducedBmi/ cells were expressed relative to the levels in untransduced
Bmi1/ c-Kit+ cells.
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Bmi1 and Hox Crosstalk in Establishment of LSCsa senescence-associated b-galactosidase (SA-b-gal) assay and
annexin V staining in primary hematopoietic cells derived from
wild-type and Bmi1/ backgrounds to assess senescence
and apoptosis, respectively. We were able to demonstrate
a significant induction (in about 45% of the cells) of SA-b-gal
activity in Bmi1/ cells transduced with AE or PR, which was
suppressed to almost the basal level upon re-expression of
Bmi1 (Figure 2I). In contrast, the level of apoptosis, as deter-
mined by annexin V staining, did not reveal a major difference
between Bmi1/ cells transduced with CTFs and Bmi1 rescue
(Figure S2E). Together, these results suggest that the require-
ment for Bmi1 in leukemogenic transformation by AE and PR
could be, in part, explained by its ability to limit OIS induced by
these CTFs.
Hoxa9 Is Differentially Activated by MLL Fusions,
but Not by AE or PR
To identify the factors that may influence Bmi1 dependency, we
compared the expression profiles of 84 AML patients carrying
specific genetic abnormalities including AE (n = 38), RARa
fusions (n = 30 including 26 PML-RARa and 4 PLZF-RARa),
and MLL fusions (n = 16) (Rice et al., 2009; Valk et al., 2004;
Verhaak et al., 2009). Consistent with previous findings on
MLL-mediated activation of HOX genes reported by others and
us (Cheung et al., 2007; Milne et al., 2002; Okada et al., 2005),
here we found that a major difference between MLL fusions
and AE/RARa fusions was the significant expression of HOXA
genes (HOXA7,HOXA9) andMEIS1 in MLL leukemia (Figure 3A).
Similar results were also observed in our murine models where
MAF9, but not AE or PR, fusion-transduced cells expressed
high levels of these two Hox genes and Meis1 (Figure 3B).
Consistent with the previous findings on Bmi1/ HSCs, the
expression of Hox genes including Hoxa9 in CTF-transduced
cells were not significantly altered in the absence of Bmi1 (Fig-
ure 3B, left and middle panels, lane 2 and lane 6), suggesting
that at least some of these Hox genes with alleged self-renewal
properties may still function in the absence of Bmi1. This is also
consistent with the observation that Bmi1/ cells retain limited
self-renewal properties that allow Bmi1-deficient mice to
develop into adulthood. Because both previous overexpression
(Bach et al., 2010) and knockout mice studies (Lawrence et al.,
2005; So et al., 2004) have demonstrated a dominant function
of Hoxa9 over Hoxa7 in cellular transformation and maintaining
normal HSCs, we generated Bmi1/Hoxa9/ compound
knockout (KO) mice to assess the functional interplay between
Bmi1 and Hoxa9 in the development of normal hematopoietic
and leukemic stem cells.
Hoxa9 Supports Hematopoiesis in the Absence of Bmi1
Although Bmi1/Hoxa9/ mice were viable, they were sterile
and usually died within 6–10 weeks mostly as a result of anemia,
compared with Bmi1/ mice with a life span of up to 20 weeks
(data not shown). Further analyses of age-matched wild-type
and knockout mice revealed that Bmi1/Hoxa9/ mice had
a significant reduction in the cell number in all the hematopoietic(H) Typical immunoblot of p16 in wild-type and Bmi1/ cells transformed with in
(I) Representative SA-b-gal staining of primary BM cells transduced with indicated
positive cells using the indicated constructs. *p < 0.05. All error bars represent Sorgans analyzed including the bonemarrow, spleen, and thymus
compared to eitherBmi1/ orHoxa9/ single KOmice (Figures
3C–3E; Figures S3A–S3D), suggesting hematopoietic defects
within the HSC and/or early progenitors compartments. Consis-
tently, although knockout of Hoxa9 alone did not lead to a
reduction in the absolute number or percentage of LinSca1+kit+
(LSK) cells (So et al., 2004) (Figure 3F; Tables S1 and S2),
Bmi1/Hoxa9/ mice had a greater than 3-fold reduction in
the absolute number of LSK cells in the bone marrow compared
with Bmi1/ mice (Figure 3F; Figure S3H; Tables S1 and S2).
Using a combination of Flt3 and CD34 as additional markers to
further differentiate between long-term HSCs (LT-HSCs), short-
term HSCs (ST-HSCs), and multipotent progenitors (MPPs)
within the LSK population, we consistently found a significant
3-fold reduction of LT-HSCs in Bmi1/Hoxa9/ mice as
compared with Bmi1/ mice (Figures 3G–3H; Figures S3E–
S3J; Tables S1 and S2), suggesting defects originated as early
as the LT-HSC stage. Consistent with a stem cell defect, we
observed drastic reductions in cell numbers for the downstream
myeloid progenitors (Tables S1 and S2) including common
myeloid progenitors (CMPs), granulocyte and macrophage
progenitors (GMPs), and megakaryocyte and erythrocyte
progenitors (MEPs) (Figures 3I–3K; Figures S3K–S3M), whereas
its impact on common lymphoid progenitors (CLPs) was rela-
tively mild (Figure 3L; Figure S3N; Tables S1 and S2). In line
with the documented roles of Hoxa9 in T cell development (Law-
rence et al., 1997; So et al., 2004), profound defects were found
in the thymus of Bmi1/Hoxa9/ mice. Three out of four
subpopulations of pro-T cells (Figures S3O and S3R), CD4/
CD8 double-negative (Figure S3S), CD4/CD8 double-positive
(Figure S3T), and CD4 or CD8 single-positive T cells (Figures
S3U and S3V) were significantly reduced in Bmi1/Hoxa9/
mice relative to the single KO mice. Further functional assays
revealed that Bmi1/Hoxa9/ bone marrow cells generated
reduced numbers of lymphoid and myeloid colonies in vitro (Fig-
ure S3W), in which most of latter was more mature CFU-G (Fig-
ure S3X). Bmi1/Hoxa9/ bone marrow cells also failed to
achieve long-term repopulation (8+ weeks) although they were
able to engraft with compromised ability for short-term reconsti-
tution (4 weeks) (Figures S3Y and S3Z). Together, these results
suggest that Hoxa9 plays a critical role in establishment of
HSCs and sustaining normal hematopoiesis in the absence of
Bmi1.
Deletion of Hoxa9 Completely Abolishes
MAF9-Mediated Transformation of Bmi1-Deficient Cells
To further study the function of Hoxa9 in mediating Bmi1-inde-
pendent transformation, we transduced MAF9 into c-Kit-en-
riched hematopoietic cells derived from wild-type, Bmi1/,
Hoxa9/, and Bmi1/Hoxa9/ mice. As expected, MAF9
could efficiently transform wild-type, Hoxa9/ (Kumar et al.,
2004), and Bmi1/ cells, and generated compact third-round
colonies with the immunophenotype and morphology consistent
of myeloid precursors (Figures 4A–4D). In contrast, although
MAF9could transduceBmi1/Hoxa9/cells to formfirst-rounddicated constructs.
constructs. Scale bar, 50 mm. Bar charts indicate the percentage of SA-b-gal-
D from at least three independent experiments (see also Figure S2).
Cell Stem Cell 8, 649–662, June 3, 2011 ª2011 Elsevier Inc. 653
0.0
0.5
1.0
1.5
2.0
2.5
3.0
H
o
x
a
7
 e
x
p
r
e
s
s
io
n
 f
o
ld
 
c
h
a
n
g
e
DC E
F G H I J K L
A
B
ns
ns
*
*
0
5
10
15
20
25
H
o
x
a
9
 e
x
p
r
e
s
s
i
o
n
 f
o
l
d
 
c
h
a
n
g
e
ns
ns
*
* *
ns
*
*
ns ns
ns
R
e
l
a
t
i
v
e
H
o
x
a
7
e
x
p
r
e
s
s
i
o
n
l
e
v
e
l
s
R
e
l
a
t
i
v
e
H
o
x
a
9
e
x
p
r
e
s
s
i
o
n
l
e
v
e
l
s
R
e
l
a
t
i
v
e
M
e
i
s
1
e
x
p
r
e
s
s
i
o
n
l
e
v
e
l
s
wt
Bm
i1
-/-
Bm
i1
-/- Ho
xa
9
-/-
Ho
xa
9
-/-
wt
Bm
i1
-/-
Bm
i1
-/- Ho
xa
9
-/-
Ho
xa
9
-/-
wt
Bm
i1
-/-
Bm
i1
-/- Ho
xa
9
-/-
Ho
xa
9
-/-
wt
Bm
i1
-/-
Bm
i1
-/- Ho
xa
9
-/-
Ho
xa
9
-/-
wt
Bm
i1
-/-
Bm
i1
-/- Ho
xa
9
-/-
Ho
xa
9
-/- wt
Bm
i1
-/-
Bm
i1
-/- Ho
xa
9
-/-
Ho
xa
9
-/-
wt
Bm
i1
-/-
Bm
i1
-/- Ho
xa
9
-/-
Ho
xa
9
-/-
wt
Bm
i1
-/-
Bm
i1
-/- Ho
xa
9
-/-
Ho
xa
9
-/-
wt
Bm
i1
-/-
Bm
i1
-/- Ho
xa
9
-/-
Ho
xa
9
-/-
wt
Bm
i1
-/-
Bm
i1
-/- Ho
xa
9
-/-
Ho
xa
9
-/-
wt
Bm
i1
-/-
Bm
i1
-/- Ho
xa
9
-/-
Ho
xa
9
-/-
wt
Bm
i1
-/-
Bm
i1
-/- Ho
xa
9
-/-
Ho
xa
9
-/- wt
Bm
i1
-/-
Bm
i1
-/- Ho
xa
9
-/-
Ho
xa
9
-/-
wt
Bm
i1
-/-
Bm
i1
-/- Ho
xa
9
-/-
Ho
xa
9
-/-
wt
Bm
i1
-/-
Bm
i1
-/- Ho
xa
9
-/-
Ho
xa
9
-/-
wt
Bm
i1
-/-
Bm
i1
-/- Ho
xa
9
-/-
Ho
xa
9
-/-
wt
Bm
i1
-/-
Bm
i1
-/- Ho
xa
9
-/-
Ho
xa
9
-/-
LSK LSK FLT3-(LT-HSC)
LSK FLT3+
(ST-HSC/MPP) CMP GMP CLPMEP
% LSK % LSK FLT3-(LT-HSC)
% LSK FLT3+
(ST-HSC/MPP) % CMP % GMP % CLP% MEP
Bone Marrow Spleen Thymus
Figure 3. Hox Genes Were Upregulated by MLL Fusions, and Deletion of Hoxa9 Worsened Hematopoietic Defects in Bmi1–/– Mice
(A) Pairwise correlations between gene expression profiles of a collection of human AML samples withMLL- [11q23], AML-ETO [t(8;21)], PLZF-RARa [t(11;17)],
and PML-RARa [t(15;17)] fusions, selected from an original cohort of 530 samples. Colors of the boxes visualize Pearson correlation coefficient: deeper red
indicates higher positive correlation; deeper blue indicates higher negative correlation. Green versus red bars: red indicates the cases carrying the indicated
translocation. Relative mRNA expression levels of BMI1, MEIS1, HOXA7, and HOXA9 are indicated in the brown bars next to each patient.
(B–L) (B) Expression of Hoxa7, Hoxa9, and Meis1 in wild-type and Bmi1/ primary BM cells and those transduced with the indicated constructs. Expression
levels are expressed relative to levels in wild-type c-Kit+ cells. Total cell number in the BM (C), spleen (D), and thymus (E) of wild-type (n = 12), Bmi1/ (n = 5),
Bmi1/Hoxa9/ compound KO (n = 6), andHoxa9/ (n = 8) mice. Eachmouse is represented by a symbol; the horizontal line indicates the mean. The absolute
number (upper panels) and percentage (lower panels) of LSK (F), LT-HSC (G), ST-HSC/MPP (H), CMP (I), GMP (J), MEP (K), and CLP (L) populations in indicated
mice. *p < 0.05; ns indicates p > 0.05 (see also Figure S3 and Tables S1 and S2).
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Bmi1 and Hox Crosstalk in Establishment of LSCscolonies, they quickly exhausted their proliferative potential and
failed to produce second- or third-round colonies (Figures 4A–
4D), suggesting that Hoxa9 plays a specific role in sustaining
MAF9-mediated transformation in the absence of Bmi1.
Functional complementation experiments were performed
using Bmi1/Hoxa9/-deficient cells transduced with MAF9
in combination with Bmi1 or Hoxa9. All MAF9-transduced cells
yielded a similar number of first-round colonies that expressed
a similar level of MAF9 transcript (Figures S4A and S4B).
Reintroduction of either Bmi1 or Hoxa9 could efficiently rescue
the MAF9 transformation phenotype in Bmi1/Hoxa9/-defi-
cient cells (Figure 4A). Cotransduced cells produced compact
colonies in the third and subsequent rounds of plating with
immunophenotype and morphology consistent with myeloid
precursors (Figures 4B–4D; data not shown). To further investi-
gate whether re-expression of Hoxa9 could completely rescue
the transformation defect of MAF9 in the Bmi1/Hoxa9/
background, we serially transplanted the Hoxa9 rescued cells
into syngeneic mice. As a result, half of the mice transplanted
with the Bmi1/Hoxa9/ cells carrying MAF9 and Hoxa9
developed leukemia within 4 months (Figure 4E). Furthermore,
serial transplantation experiments showed that these cells
could efficiently transfer leukemia to secondary and even
tertiary recipient mice (Figure 4E). Leukemic cells from serial
transplants had an immunophenotype consistent with immature
myeloid precursors (Figure 4F), which also infiltrated the spleen
and, to a much lesser extent, the liver (Figure 4G). Together,
these results suggest that Hoxa9 allows establishment and
sustains long-term self-renewal of LSCs induced by CTFs in
the absence of Bmi1.
Hoxa9 Suppresses Replicative and Oncogene-Induced
Senescence
Because an important function of Bmi1 is to suppress the
expression of the cdkn2a locus, which acts as a major regulator
for senescence, and deletion of p16Ink4a/p19Arf can partially
rescue the self-renewal defects in Bmi1/-deficient cells of
hematopoietic and neuronal origin (Sauvageau and Sauvageau,
2010), the expression of p16Ink4a and p19Arf was assessed in
MAF9-transduced cells. There was a modest induction of
p16Ink4a and p19Arf expression by MAF9 in the absence of
Bmi1 or Hoxa9 (Figure 4H). However, a significant induction
was observed when both Bmi1 and Hoxa9 were inactivated (Fig-
ure 4H; Figures S4C and S4D), suggesting a complementary
function in regulating these cell-cycle inhibitors. Consistently,
expression of Bmi1 or Hoxa9 in cells derived from the double
knockout suppressed the induction of p16Ink4a and p19Arf
induced by MAF9 (Figure 4H), suggesting a putative function of
Hoxa9 in regulating senescence, a critical cellular checkpoint
for normal and leukemic stem cells.
To investigate the possible involvement of Hoxa9 in regulating
cell senescence, we employed both well-established primary
fibroblasts and primary hematopoietic cell models. IMR90
human fibroblasts at a passage close to the onset of senescence
were transduced with a vector expressing Hoxa9, an empty
vector control, or a vector knocking down p16INK4a expression.
After selection, the proliferative potential of the cells was as-
sessed by colony formation assays. Similar to p16INK4a knock-
down, expression of Hoxa9 conferred a proliferative advantageto IMR90 cells (Figures 5A and 5B), consistent with a function
of Hoxa9 in regulating senescence. To further investigate the
role of Hoxa9 in senescence, we took advantage of an inducible
system of OIS (Barradas et al., 2009). Primary human fibroblasts
carrying inducible Ras oncogene were infected with Hoxa9, a
shRNA targeting p16INK4a or vector control. Upon addition of
4-hydroxytamoxifen (4-OHT) to induce Ras expression, cells
transfected with vector control underwent senescence, as
observed by reduced incorporation of BrdU and cell growth,
characteristic senescent morphology, and induction of
p16INK4a expression (Figures 5C and 5D; data not shown). In
contrast, cells infected with a shRNA targeting p16INK4a or
Hoxa9 expression vector partially bypassed OIS and were
capable of forming colonies (Figure 5C). When examining the
expression of p16INK4a in these cells, Hoxa9 partially inhibited
the induction of p16INK4a expression observed during OIS (Fig-
ure 5D). To further understand how Hoxa9 could control the
expression of the INK4a/ARF locus, we performed transcription
assays using luciferase reporters driven by the p16INK4a pro-
moter. As expected, ETS2, a known activator of CDKN2A locus,
(Ohtani et al., 2001) differentially activated reporter gene expres-
sion driven by p16INK4a promoter (Figure 5E). In contrast, Hoxa9
suppressed the basal level of expression of luciferase reporter
genes driven by p16INK4a promoters (Figure 5E). More impor-
tantly, coexpression of Hoxa9 significantly suppressed activa-
tion of the p16INK4a promoter by ETS2 (Figure 5E). Interestingly,
a putative homeobox binding site has recently been identified in
CDKN2A locus (Irelan et al., 2009). To determine whether Hoxa9
could indeed bind to this locus, we carried out chromatin immu-
noprecipitation (ChIP) using IMR90 human fibroblasts or primary
murine hematopoetic cells expressing Flag-tagged Hoxa9. A
significant enrichment of Hoxa9 binding to the CDKN2A locus
was detected in both cell types, consistently suggesting the
CDKN2A locus as a direct transcriptional target of Hoxa9,
although further work is required to define the precise binding
regions (Figures 5F and 5G; Figure S5A). Because Meis1 is
frequently coexpressed with Hox in MLL leukemia (Figures 3A
and 3B), we investigated whether Meis1 was also required for
the regulation of senescence mediated by Hoxa9. IMR90
primary human fibroblasts were sequentially transfected with
either a vector control or Hoxa9, and siRNAs targeting either
p16INK4A (Bishop et al., 2010) or Meis1 (Figure S5B). As ex-
pected, expression of Hoxa9 effectively suppressed p16INK4A
levels (Figure S5C). However, in contrast to p16INK4A siRNA
control, sequential knockdown of Meis1 expression by three
different shRNAs did not significantly affect the percentage of
p16INK4a-positive cells or BrdU incorporation either in the
absence or presence of Hoxa9 (Figures S5D), suggesting that
Meis1 may not be directly involved in regulating cell senescence
under these conditions. Together, these results reveal a function
of Hoxa9 in regulating senescence.
Hoxa9 Rescues AE Oncogene-Induced Senescence
in the Absence of Bmi1
Because we previously showed that AE and PR induced senes-
cence in the absence of Bmi1, we sought to determine whether
Hoxa9 could also suppressOIS induced by leukemia-associated
CTFs in the absence of Bmi1. Analogous to the overexpression
of Bmi1 or specific knockdown of p16Ink4a and p19Arf expressionCell Stem Cell 8, 649–662, June 3, 2011 ª2011 Elsevier Inc. 655
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Figure 4. Deletion of Hoxa9 Completely Abolished MLL-AF9-Mediated Transformation of Bmi1-Deficient Cells
(A) Bar chart represents number of colonies in each round of plating in methylcellulose for the indicated constructs.
(B) Typical morphology of third-round colonies of wild-type, Bmi1/, Hoxa9/, and Bmi1/Hoxa9/ cells transformed with indicated constructs. Scale bar,
0.2 mm.
(C) Typical cell morphology of primary BM cells transduced with the indicated constructs after three rounds of plating. Scale bar, 10 mm.
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Bmi1 and Hox Crosstalk in Establishment of LSCsby a shRNA targeting exon 2 of the cdkn2a locus, forced expres-
sion of Hoxa9 was able to rescue the Bmi1-dependent transfor-
mation mediated by AE (Figure 6A). Although both AE control
and AE/Hoxa9 cotransduced cells generated a similar number
of first-round colonies (Figure S6A), only the latter formed
compact colonies in the third and subsequent rounds of replat-
ing with similar morphology (Figure 6B) and immunophenotype
(Figure 6C) as the wild-type transformed cells. Coexpression of
AE with Hoxa9 in Bmi1/ cells increased the percentage of
BrdU-positive cycling cells (Figure 6D), rescued the proliferation
defect (Figure 6E), and reduced the percentage of senescent
cells (as assessed by SA-b-gal staining in Figure 6F) in AE-trans-
duced Bmi1/ cells to a similar extent as compared with those
rescued by Bmi1 overexpression. Hoxa9 also prevented the
induction of p16Ink4a and p19Arf expression by AE in Bmi1/
cells (Figures 6G and 6H), consistently supporting the role of
Hoxa9 in regulating OIS for development of LSCs.
DISCUSSION
Although Bmi1 has previously been shown to be an essential
molecule required for LSCs induced by overexpression of
Meis1 and Hoxa9, we illustrate that the requirement of Bmi1
for the establishment of AML stem cells differs vastly depending
on the nature of the initiating events. As a result of gene fusion,
CTFs acquire aberrant transcriptional and epigenetic properties
that can initiate novel and distinctive transcriptional programs to
convert early progenitors/stem cells into preLSCs and subse-
quently LSCs (Greaves and Wiemels, 2003; Hong et al., 2008;
Yeung et al., 2010). In contrast to AML1 and RARa fusions that
act as dominant transcriptional repressors, MLL fusions aber-
rantly recruit transcriptional activators such as Dot1L (Okada
et al., 2005) and Prmt1 (Cheung et al., 2007) to mediate epige-
netic reprogramming to induce stem cell-like transcriptional
programs including activation of multiple Hox genes (Krivtsov
et al., 2006, 2008; So et al., 2004; Zeisig et al., 2008). Interest-
ingly, Hox genes have also been suggested as downstream
targets of RARa and AML1-fusions (Look, 1997), which may
increase the Bmi1-dependence of these fusions for suppression
of OIS. Thus, the proposed function of theHox gene in suppress-
ing cellular senescence may constitute a critical determinant for
Bmi1-independent establishment and maintenance of LSCs by
different CTFs (Figure 7).
In comparison to Meis1/Hoxa9 oncogenes, MLL fusions
acting directly upstream of these two proteins can activate an
even larger array of transcriptional programs including multiple
Hox genes and nonHox targets. Although it is evident that over-(D) Immunophenotype analysis of cells transformed by indicated constructs. C
indicated cell surface markers. Dot profiles show unstained controls.
(E) Mice injected with Bmi1/Hoxa9/ compound KO cells transduced with
transplantable into secondary (second, n = 10) and tertiary mice (third, n = 5). Di
result in leukemia (control, n = 10). *p < 0.05 when comparing the survival curve
(F) Immunophenotype analysis of leukemic cells recovered from BM of injected
indicated cell surface markers. Contour profiles show unstained controls.
(G) Histology of spleen and liver from leukemic mice injected with Bmi1/Hoxa9
(H) p16INK4a (left) and p19ARF (right) expression levels in primary hematopoietic
indicated constructs. Values were expressed relative to levels in Bmi1/ c-Kit+
experiments (see also Figure S4).expression of a single Hox gene is not sufficient to fully rescue
the self-renewal defect associated with loss of Bmi1, forced
expression of Hoxb4 alone can lead to expansion of short-term
repopulating HSCs in the absence of Bmi1 (Faubert et al.,
2008) in spite of a lack of long-term reconstitution potential
(Iwama et al., 2004). Similarly, Bmi1/ cells transformed by
Hoxa9/Meis1 can still induce malignant myeloid expansion and
acute leukemia in primary transplanted mice (Lessard and Sau-
vageau, 2003). The finding thatMLLCTFs acting as amasterHox
activator can overcome Bmi1 dependency supports the notion
that synergistic activation of multiple Hox genes may allow
Bmi1-independent self-renewal. However, given the absolute
Bmi1-dependent self-renewal of LSCs induced by Meis1/
Hoxa9, other nonHox MLL targets may also cooperate with
Hox in the process of the Bmi1-independent transformation.
MLL fusions have been shown to directly regulate expression
of cell-cycle inhibitors such as p27Kip1 (Liu et al., 2009). Although
further studies dissecting the multifaceted transcriptional func-
tions of MLL fusions will be needed to identify novel candidates
accounting for the Bmi1 independence, the current results
clearly indicate that Bmi1 requirement is oncogene dependent
and that therapeutic targeting of Bmi1 alone may not be suffi-
cient for eradication of certain cancer stem cells.
Although Hox genes have been implicated in the self-renewal
of HSCs, a complete knockout of any single or multiple Hox
gene(s), including Hoxa9, has no or very modest effects on
HSC development (Bijl et al., 2006; Bjo¨rnsson et al., 2003;
Brun et al., 2004; Lawrence et al., 2005; So et al., 2004), suggest-
ing the presence of nonHox complementary pathways. Although
Hoxa9 is largely dispensable for establishment of normal HSCs
in the wild-type background (So et al., 2003), it plays a critical
role in the generation of HSCs and for maintaining normal hema-
topoiesis in the absence of Bmi1. Similarly, whereas Hoxa9 is
normally dispensable for transformation mediated by a number
of MLL fusions including MAF9 and MLL-GAS7 (Kumar et al.,
2004; So et al., 2004), it becomes essential for the establishment
of MAF9 LSCs in the absence of Bmi1, revealing a critical func-
tional interplay between these two molecular pathways in estab-
lishment of normal and leukemic stem cells. In contrast to the
PcG protein, CBX7, whose overexpression partially prevents
Bmi1-dependent senescence by a mechanism reliant on PRCs
function (Gil et al., 2004), Hoxa9 has not been reported to be
part of the PRCs. Although Hoxa9 may have multiple functions,
its direct binding and transcriptional repression of the CDKN2A
locus suggest that Hoxa9 may partially replace Bmi1 function
by suppressing cellular senescence, although the precise
interplay between Hoxa9 and PRCs remains to be established.ontour profiles represent staining obtained with antibodies specific for the
MAF9 and Hoxa9 develop myeloid leukemia (n = 9), which were serially
rect injection of Bmi1/Hoxa9/ cells transformed with MAF9 (n = 8) did not
to the control.
mice. Dot profiles represent staining obtained with antibodies specific for the
/: MAF9 + Hoxa9 cells. Scale bar, 10 mm.
cells derived from different KO or wild-type backgrounds transduced with
cells. *p < 0.05. All error bars represent SD from at least three independent
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Figure 5. Hoxa9 Suppressed Replicative and Oncogene-Induced Senescence
(A) IMR90 primary human fibroblasts transduced with the indicated vectors were fixed and stained with crystal violet after 10–15 days.
(B) Immunophenotype of p16 in IM90 cells overexpressing indicated constructs. Right-hand chart indicates percentage of p16INK4a-positive cells observed.
*p < 0.05.
(C) IMR90 ER:Ras cells were infected with vector control, Hoxa9, or a shRNA targeting human p16INK4a. Top row shows crystal violet stained cells, lower shows
bright field images.
(D) Immunofluorescence staining of p16INK4a in IMR90 ER:Ras human fibroblast 4 days after 4-OHT induction. Right-hand chart indicates percentage of
p16INK4a-positive cells observed.
(E) Luciferase assay with p16INK4a promoter-driven reporter.
(F) Bar charts show the relative binding of Hoxa9 (by Flag-antibody) to CDKN2A or PGK1 loci in human fibroblasts expressing Flag-tagged Hoxa9 or vector
control.
(G) Bar charts show the relative binding of Hoxa9 (by Flag-antibody or Hoxa9 antibody) to cdkn2a or gapdh loci in primary murine hematopoietic cells expressing
Flag-tagged Hoxa9. *p < 0.05; ns indicates p > 0.05. All error bars represent SD from at least three independent experiments (see also Figure S5).
Cell Stem Cell
Bmi1 and Hox Crosstalk in Establishment of LSCsInterestingly, HOXA9 has been identified as one of the most
significant independent poor prognostic markers for AML, but
very little is known about its functions and critical downstream
targets (Golub et al., 1999). The newly discovered functional
interplay of Hoxa9 with Bmi1 in development of normal and
leukemic stem cells will provide a potential molecular explana-
tion for its role in influencing AML prognosis. Hoxa9 can regulate
Ink4a/Arf expression and cellular senescence in the presence
(Figure 5) or absence of Bmi1 (Figure 6). In this model, we658 Cell Stem Cell 8, 649–662, June 3, 2011 ª2011 Elsevier Inc.propose that both Bmi1 and Hox can function to suppress
cellular senescence, whereby one of the pathways is needed
to overcome OIS by certain CTFs (Figure 7). In contrast to AE
and PR, which are critically dependent on Bmi1 for their transfor-
mation, MLL CTFs that are capable of activating multiple Hox
targets can bypass Bmi1 requirement. These findings reveal an
unexpected cooperative function between Bmi1 and MLL/Hox,
and that a synergistic targeting of both molecules may be
required for elimination of certain cancer stem cells (Figure 7).
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Figure 6. Hoxa9 Rescued Oncogene-Induced Senescence by AE in the Absence of Bmi1
(A) Bar charts represent colony number in each round of plating in methylcellulose.
(B) Typical morphology of third-round colonies (top; scale bar, 0.2mm) and cell morphology (bottom; scale bar, 10 mm) fromBmi1/ primary BMcells transduced
with the indicated constructs.
(C) Immunophenotype analysis of cells transformed by the indicated constructs. Dot profiles represent staining obtained with antibodies specific for the indicated
cell surface markers. Contour profiles show unstained controls.
(D) Bar charts show proportion of cycling cells (BrdU+) or noncycling cells (BrdU) in AE-transformedWT or Bmi1/ primary BMwith or without reintroduction of
Bmi1, Hoxa9, or shp16/ARF.
(E) The bar chart indicates the fold change in cell number after 1 week in OP9 coculture asasys.
(F) Typical SA-b-gal staining of primary BM cells transduced with indicated constructs. Scale bar, 50 mm. Bar charts indicate the percentage of SA-b-gal-positive
cells induced by the indicated constructs.
(G) p16INK4a (left) and p19ARF (right) expression levels expressed relative to levels in Bmi1/ c-Kit+ cells. *p < 0.05. All error bars represent SD from at least three
independent experiments.
(H) Typical immunoblot of p16 in wild-type and Bmi1/ cells transduced with indicated constructs (see also Figure S6).
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Figure 7. Bmi1 and Hox Can Function to Suppress Cellular Senes-
cence
(A–C) (A) Bmi1 and Hox proteins may function to suppress expression of the
Ink4a/Arf locus to preserve HSCs pool. In the context of leukemia, formation of
an oncogenic fusion protein confers proliferative advantage but also induces
OIS of the targeted hematopoietic cells. Depending on the nature of these
initiating events and the origin of the targeted cells (e.g., stem cells versus
progenitors), certain oncoproteins, such as AE/PR, are completely dependent
on Bmi1 to suppress OIS (B). Other oncogenes, such as MLL fusions, which
can activate multiple Hox genes, exhibit a modest dependence on Bmi1
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Constructs
MSCV retroviral plasmids encoding full-length AE, PR, and MLL-AF9 cDNA
have been previously described (Cheung et al., 2007; Kwok et al., 2006,
2009; Wong et al., 2007).
Retroviral Transduction Transplantation Assay
Retroviral Transduction Transplantation Assay (RTTA) was performed as previ-
ously described (Zeisig and So, 2009). Briefly, c-Kit+ cells were isolated from
murine bone marrow (BM) using CD117 MicroBeads (Miltenyi Biotech) and
were cultured overnight in R10 medium (see Supplemental Information)
supplemented with 20 ng ml1 stem cell factor (SCF), 10 ng ml1 interleukin
(IL)-3, and 10 ng ml1 IL-6. 4 3 104 Bmi1/ or Bmi1/Hoxa9/ or 2 3 104
WT c-Kit+ cells were transduced for each test condition. Concentrated viral
supernatant was used for transduction by centrifugation at 800 3 g in the
presence of 5 mg ml1 polybrene (Sigma-Aldrich) at 32C for 2 hr. A second
transduction was performed on the following day. Cells were subsequently
plated into 1%methylcellulose medium (M3231; Stem Cell Technologies) con-
taining 20 ng ml1 SCF, 10 ng ml1 IL-3, 10 ng ml1 IL-6, and 10 ng ml1 gran-
ulocyte macrophage colony-stimulating factor (GM–CSF) and appropriate
selection antibiotic. Colonies were scored after 7 days of culture and replated
every 7 days. After the third or fourth round of plating, cells were cultured in
R20/20 (see Supplemental Information) to establish cell lines. All recombinant
murine cytokines were purchased from PeprotechEC.
Immunophenotype Analysis
Immunophenotype analysis of cells was performed by flow cytometry as
previously described (Cheung et al., 2007; Kwok et al., 2006) and detailed in
the Supplemental Experimental Procedures. Immunophenotype analysis of
hematopoietic compartments in the knockout mice was performed as
described (So et al., 2004; Yeung and So, 2009) and detailed in the Supple-
mental Experimental Procedures.
Proliferation Coculture and Cycling Assays
Cells from the RTTA assays were used in OP9 coculture and BrdU incorpora-
tion assays. BrdU incorporation was determined by flow cytometry using FITC
BrdU Flow Kit (BD Biosciences) following manufacturer’s instructions after
incubating cells for 20 hr with BrdU. Details of cell culture are provided in
the Supplemental Experimental Procedures. For coculture studies, OP9 cells
were irradiated at 30 Gy and plated at a density of approximately 1 3 104
cells/cm2 in 12-well plates. 4 3 105 hematopoietic cells were seeded on the
following day and were counted after a week of growth before 2 3 105 cells
were plated into methylcellulose for clonogenic formation assay as described
in RTTA.
Experimental Animals and In Vivo Assays
Bmi1+/ mice (van der Lugt et al., 1994) were crossed with Hoxa9/ mice
(So et al., 2004) to obtain Bmi1+/Hoxa9/ mice and, subsequently,
Bmi1/Hoxa9/ compound KO mice. For transplantation experiments to
determine leukemogenicity of test cells, C57BL/6 or SJL mice were given
12.5 Gy total body g-irradiation and injected intravenously with 1 3 106 test
cells mixed with 0.2 3 106 C57BL/6 or SJL mononuclear BM cells. Control
mice were injected with 0.2 3 106 C57BL/6 or SJL mononuclear BM cells.
All experimental procedures were approved by the King’s College London
and Institute of Cancer Research animal welfare and ethics committees and
conformed to the UK Home Office regulations.
Senescence-Associated b-galactosidase Staining
Cytospins of cells from RTTAs were fixed with 0.5% glutaraldehyde (w/v) for
15min and thenwashed twicewith 1mMMgCl2 in PBS (pH 6.0). X-Gal staining
solution (1 mg ml1 X-Gal, 5 mM K3[Fe(CN)6], and 5 mM K4[Fe(CN)6] in 1 mM
MgCl2/PBS (pH 6.0)) was added to the cells for 2–24 hr, after which the cellsfunction (C). For the latter, synergistic targeting of both Bmi1 and Hox path-
ways may be required to eradicate LSCs.
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Bmi1 and Hox Crosstalk in Establishment of LSCswere washed with water. Pictures of cytospins were taken using a Wolfe
XD-202 microscope with a GXCAM-3 camera using GXCapture software
(GX Optical). The percentage of SA-b-gal-positive cells was determined
upon counting of at least 200 cells.
Chromatin Immunoprecipitation
ChIP was performed as previously described (Ananthanarayanan et al., 2004)
with minor modifications using the EZ-Magna ChIPTM G kit (cat no. 17-409,
Millipore). Immunoprecipitation of crosslinked chromatin was conducted
with anti-FLAG mouse monoclonal magnetic beads (Sigma-Aldrich cat no.
M8823-5). After immunoprecipitation, DNA was extracted using the QIAquick
PCR purification kit (QIAGEN) and an aliquot amplified by real time qPCR using
oligonucleotide primers described in the Supplemental Experimental Proce-
dures. To confirm target enrichment, we evaluated each PCR product first
by standard endpoint PCR. ChIP on primary murine cell lines was performed
as previously described (Barradas et al., 2009; Cheung et al., 2007).
Detailed procedures for cell culture, immunophenotype analysis, annexin V
staining, immunofluorescence staining, crystal violet staining, qPCR, western
blotting, luciferase reporter assay, and statistical analysis are in the Supple-
mental Information.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, two tables, and Supplemental
Experimental Procedures and can be found with this article online at
doi:10.1016/j.stem.2011.05.004.
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